30 results about "Chlamydia trachomatis infection" patented technology

The invention discloses a method for the treatment or prevention of ocular Chlamydia trachomatis infection by the administration of a safe and effective amount of an immunogenic composition comprising one or more Chlamydia trachomatis proteins, immunogenic fragments thereof or polynucleotides encoding said proteins or fragments, selected from the list consisting of Swib, Momp, Ct-858, Ct-875, Ct-622, Ct-089, passenger domain of PmpG (PmpGpd) and passenger domain of PmpD (PmpDpd).

The invention provides a kit for detecting chlamydia trachomatis (CT). The kit comprises a nucleic acid releaser and a PCR (Polymerase Chain Reaction) solution, wherein the nucleic acid releaser comprises 0.01-0.5mM / L of surfactin, 20-300mM / L of potassium chloride, 0.01-2% of sodium dodecyl sulfate and 0.05-1% of ethanol; and the PCR solution comprises a forward primer and a reverse primer which are used for amplifying targeted polynucleotide, and a probe for detecting the targeted polynucleotide. A method of releasing nucleic acid by using the nucleic acid releaser in the kit provided by the invention is not obviously different from a boiling method in the detection result, and a violent protein denaturant adopted for the nucleic acid extraction in the method provided by the invention quickly breaks a coat protein structure of a pathogen to release pathogen nucleic acid, so the release and extraction of DNA (Deoxyribonucleic Acid) can be realized without heating; besides, the sensitivity of the provided kit for detecting the CT can be 400 copies / ml, the linearity region of the detection is 400-4.00E+10 copies / ml; and moreover, CT-DNA in an unknown sample such as genital secretions can be quickly and precisely detected by using the kit, so a reliable experiment basis is provided for diagnosing CT infection.

The invention aims at providing a kit which is suitable for rapid test of chlamydia trachomatis in clinical samples and can be used for auxiliary diagnosis and efficacy monitoring of chlamydia trachomatis infection. The technical scheme of the invention is as follows: an PCR (polymerase chain reaction) fluorescence quantitative rapid test kit of the chlamydia trachomatis is provided and comprises a PCR reaction solution, wherein the PCR reaction solution contains primers and a fluorescence probe; and the primers comprise an upstream primer and a downstream primer, and the kit further comprises a DNA (deoxyribonucleic acid) polymerase, a strong positive quality control product, a weak positive quality control product, a negative quality control product, a positive quantitative reference product and a DNA extraction solution. According to the CT (chlamydia trachomatis) fluorescence PCR quantitative test kit and method provided by the invention, a Taqman core technology platform and an arabidopsis internal reference system are utilized, thus the test sensitivity is higher. Furthermore, the accuracy, specificity, repeatability, stability, sensitivity and precision are improved compared with those of the existing product.

The present invention provides nucleic acids, proteins and vectors for a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. trachomatis. The method employs a vector containing a nucleotide sequence encoding a Mgp002 polypeptide of a strain of Chlamydia operably linked to a promoter to effect expression of the gene product in the host. Truncated forms of the full-length Mgp002 gene are useful immunogens for protecting against disease caused by infection with Chlamydia. The invention further provides recombinant Mgp002 protein useful for protecting against disease caused by infection with Chlamydia.

The invention discloses the application of small molecule inhibitors VX-11e and BVD-523 in inhibiting chlamydia infection. The study of the present invention found that the signaling pathway inhibitors VX‑11e and BVD‑523 can significantly inhibit the infection of Chlamydia trachomatis, compared with the reported MEK inhibitor U0126, there is a significant difference; the present invention is the first small molecule inhibitor VX‑11e and BVD‑523 applied to chlamydia infection, which is expected to become a new drug for chlamydia targeted host therapy; at the same time, the study also found that the combined application of inhibitors VX‑11e and BVD‑523 with azithromycin has a synergistic effect, after chlamydia infection, VX‑11e and BVD‑523 can promote the anti-infective effect of azithromycin, and have important application value for the treatment of chlamydia infection. The invention is of great significance for the development of new drugs for chlamydia trachomatis infection and for finding new targets for assisting host treatment.

A recombinant protein vaccine for preventing the infection of human chlamydia trachomatis, which is a fusion protein recombined by linking the heat shock protein 65 of BCG vaccine with the epitope of main outer membrane protein of chlamydia trachomatis, the nucleotide sequence for coding it, the expression carrier containing said nucleotide sequence, the host cell containing said expression carrier, and the process for preparing said recombinant protein vaccine are disclosed.